Entasis Therapeutics Holdings Inc
NASDAQ:ETTX
Intrinsic Value
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ETTX.
Entasis Therapeutics Holdings Inc's market capitalization is 104.8m USD.
ETTX stock price is 2.19 USD.
ETTX.
ETTX. Open DCF Valuation
ETTX. Open Relative Valuation
ETTX.
ETTX's D/E (Debt to Equity) is very low and is equal to 0.9.
ETTX's long-term assets (44m USD) exceed its long-term liabilties (27m USD).
ETTX's short-term assets (40m USD) exceed its short-term liabilties (24m USD).
ETTX's ROE (Return on Equity) has significantly decreased in the last 3 years from -128% to -170%, and is approaching profitability.
ETTX's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -763% to -684%, and is approaching profitability.
ETTX has negative Operating Income for the last twelve months.
ETTX has negative Net Income for the last twelve months.
ETTX's ROE (Return on Equity) for the past 12 months is negative and is equal to -170%.
ETTX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -684%.
ETTX has negative Net Debt. This means that the company has more cash and short-term investments (34m USD) than debt (15m USD).
ETTX has negative Free Cash Flow for the last twelve months.
ETTX has negative three-year average ROE (Return on Equity): -83%. The company is not efficient at transforming stockholders' equity into net income.
ETTX has negative three-year average ROIC (Return on Invested Capital): -982%. The company is not efficient at using invested capital to generate operating income.
ETTX's Altman Z-Score is very low and is equal to -10.12.
Fundamental Analysis
Entasis Therapeutics Holdings Inc
Balance Sheet Decomposition
Entasis Therapeutics Holdings Inc
| Current Assets | 39.9m |
| Cash & Short-Term Investments | 33.6m |
| Receivables | 1.2m |
| Other Current Assets | 5.2m |
| Non-Current Assets | 4.2m |
| PP&E | 3.9m |
| Other Non-Current Assets | 300k |
| Current Liabilities | 24.1m |
| Accounts Payable | 1.8m |
| Accrued Liabilities | 7.4m |
| Short-Term Debt | 15m |
| Non-Current Liabilities | 3.3m |
| Other Non-Current Liabilities | 3.3m |
Earnings Waterfall
Entasis Therapeutics Holdings Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-55.6m
USD
|
|
Operating Income
|
-55.6m
USD
|
|
Other Expenses
|
3.9m
USD
|
|
Net Income
|
-51.7m
USD
|
Free Cash Flow Analysis
Entasis Therapeutics Holdings Inc
ETTX Profitability Score
Profitability Due Diligence
Entasis Therapeutics Holdings Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Entasis Therapeutics Holdings Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
ETTX Solvency Score
Solvency Due Diligence
Entasis Therapeutics Holdings Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Entasis Therapeutics Holdings Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ETTX Price Targets Summary
Entasis Therapeutics Holdings Inc
Ownership
ETTX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ETTX Price
Entasis Therapeutics Holdings Inc
| Average Annual Return | -38.76% |
| Standard Deviation of Annual Returns | 15.34% |
| Max Drawdown | -83% |
| Market Capitalization | 104.8m USD |
| Shares Outstanding | 47 851 800 |
| Percentage of Shares Shorted | 0.39% |
Company Profile
Entasis Therapeutics Holdings Inc
Country
Industry
Market Cap
Dividend Yield
Description
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-09-26. The firm is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.
You don't have any saved screeners yet
